Study summary

Olaparib after treatment helped people with inherited BRCA mutations live longer

OlympiA trial (olaparib) · 1,836 people, phase 3 · Published December 2022, Annals of Oncology

89.8%alive at 4 years, vs 86.4% with placebo

What was tested

One year of olaparib, a PARP inhibitor pill, or placebo after standard treatment for high-risk HER2-negative early breast cancer in people with inherited BRCA1 or BRCA2 mutations.

What they found

What it means

Genetic testing for BRCA is now standard in TNBC because it opens this option.

Ann Oncol, via PubMed ↗ Trial record NCT02032823 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.